Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVOLVE-MS-1: Long-term safety of Vumerity in RRMS
NCT02634307Phase 3Completed
- Sponsor
- Biogen
- Start
- Dec 2015
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 3 trial of diroximel fumarate in relapsing-remitting multiple sclerosis (RRMS), sponsored by Biogen. Started Dec 2015; status: completed.
02
Drugs
diroximel fumarate
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT02634307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02634307.